← Back to Search

Antioxidant

MitoQ for Alzheimer's Disease

N/A
Waitlist Available
Led By Song-young Park, PhD
Research Sponsored by University of Nebraska
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 days
Awards & highlights

Study Summary

This trial will examine the effects of MitoQ, a mitochondria-targeting antioxidant, on carotid artery vasodilatory function and cerebrovascular blood flow in those suffering from Mild Cognitive Impairment (MCI).

Eligible Conditions
  • Alzheimer's Disease
  • Mild Cognitive Impairment

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Carotid artery blood flow
Secondary outcome measures
Brain Electrical Activity
Cerebrovascular Oxygenation
Endothelial Function
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Placebo-MitoQExperimental Treatment2 Interventions
Subjects will be tested on two different days, first day will be baseline and placebo intake, and second day will be MitoQ intake. Testing will take place 40-minutes after placebo and MitoQ intake. There will be a 2-week washout between testing days.
Group II: MitoQ-PlaceboExperimental Treatment2 Interventions
Subjects will be tested on two different days, first day will be baseline and MitoQ intake, and second day will be placebo intake. Testing will take place 40-minutes after MitoQ and placebo intake. There will be a 2-week washout between testing days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MitoQ
2006
Completed Phase 2
~230
Placebo
1995
Completed Phase 3
~2670

Find a Location

Who is running the clinical trial?

University of NebraskaLead Sponsor
537 Previous Clinical Trials
1,143,954 Total Patients Enrolled
Song-young Park, PhDPrincipal InvestigatorUniversity of Nebraska

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Effects of Mitochondrial-targeted Antioxidant on Mild Cognitive Impairment (MCI) Patients
Song-Young Park 2019. "Effects of Mitochondrial-targeted Antioxidant on Mild Cognitive Impairment (MCI) Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03514875.
~0 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top